Create Free Account

By creating account you will get access to hot stocks & personalised emails

Alterity Therapeutics Ltd

Healthcare AU ATH

0.006AUD
-(-%)

Last update at 2024-05-08T03:01:00Z

Day Range

0.0050.006
LowHigh

52 Week Range

0.0030.008
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -13.70206M -12.77705M -15.30935M -10.05968M -12.33783M
Minority interest - - - - -
Net income -13.80651M -12.84706M -15.51999M -9.69750M -11.96180M
Selling general administrative 4.94M 5.46M 6.86M 3.33M 4.28M
Selling and marketing expenses 0.05M - - - -
Gross profit 3.63M - - - 0.11M
Reconciled depreciation 0.10M 0.05M 0.08M 0.11M 0.03M
Ebit -15.28798M -17.85975M -14.50738M -10.41402M -12.71386M
Ebitda -15.18572M -17.80554M -14.43201M -10.30159M -12.68417M
Depreciation and amortization 0.10M 0.05M 0.08M 0.11M 0.03M
Non operating income net other - - - - -
Operating income -14.63614M -17.85975M -14.50738M -10.41402M -12.71386M
Other operating expenses 14.35M 15.14M 14.74M 10.07M 12.47M
Interest expense - 0.00250M 0.00000M 0.00000M 0.00000M
Tax provision 0.10M 0.07M 0.00000M 0.00000M 0.00000M
Interest income 0.02M 0.00250M 0.02M 0.33M 0.35M
Net interest income 0.02M 0.00250M 0.02M 0.02M 0.11M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.10M 0.07M 0.21M -0.36219M -0.37603M
Total revenue 3.92M 0.00250M 0.02M 0.02M 0.11M
Total operating expenses 14.35M 15.14M 14.74M 10.07M 12.47M
Cost of revenue 0.29M - - - 0.32M
Total other income expense net 0.65M 5.08M -0.80197M 0.35M 0.38M
Discontinued operations - - - - -
Net income from continuing ops -13.80651M -12.84706M -15.30935M -10.05968M -12.33783M
Net income applicable to common shares -13.80652M -12.84706M -15.30935M -13.45680M -12.33783M
Preferred stock and other adjustments - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 27.32M 41.36M 33.59M 13.30M 19.91M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.04M 0.01M 0.00936M 0.01M 0.01M
Total liab 4.50M 5.89M 3.12M 2.76M 3.36M
Total stockholder equity 22.81M 35.47M 30.47M 10.55M 16.55M
Deferred long term liab - - - - -
Other current liab 2.67M -0.02692M 1.62M 1.76M 1.63M
Common stock 213.97M 213.79M 197.45M 160.70M 156.63M
Capital stock 213.97M 213.79M 197.45M 160.70M 156.63M
Retained earnings -195.13089M -181.88439M -169.72841M -151.02194M -141.23684M
Other liab 0.02M 0.01M 0.00977M 0.04M 0.03M
Good will - - - - -
Other assets - - - - -
Cash 15.77M 34.81M 28.12M 9.20M 14.40M
Cash and equivalents - 34.81M 28.12M 0.19M 14.40M
Total current liabilities 4.38M 5.82M 3.07M 2.71M 3.32M
Current deferred revenue -0.10718M 3.10M -0.02775M -0.03288M -0.03288M
Net debt -15.56340M -34.68931M -28.04987M -9.16315M -14.36616M
Short term debt 0.11M 0.06M 0.03M 0.03M 0.03M
Short long term debt - - - - -
Short long term debt total 0.21M 0.12M 0.07M 0.03M 0.03M
Other stockholder equity -18.84043M -31.90267M -27.71958M -6.28469M 1.16M
Property plant equipment 0.27M 0.22M 0.10M 0.07M 0.05M
Total current assets 27.05M 41.14M 33.49M 13.23M 19.86M
Long term investments - - - - -
Net tangible assets 22.81M 35.47M 30.47M 7.15M 16.55M
Short term investments - - - - -
Net receivables 8.67M 4.73M 4.28M 3.46M 4.83M
Long term debt - - - - -
Inventory 2.57M 1.60M 1.09M 0.57M 0.62M
Accounts payable 1.72M 2.69M 1.45M 0.95M 1.69M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 3.57M 2.75M 0.87M 1.16M
Additional paid in capital - - - - -
Common stock total equity - - - 160.70M 156.63M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -0.26886M -0.21852M -0.09681M -0.07137M 0.05M
Deferred long term asset charges - - - - -
Non current assets total 0.27M 0.22M 0.10M 0.07M 0.05M
Capital lease obligations 0.21M 0.12M 0.07M 0.03M -
Long term debt total - 0.06M 0.04M 0.00087M 0.00000M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -0.00500M -0.08900M -0.00300M -0.01674M -0.00702M
Change to liabilities -1.56087M 2.60M 0.43M -0.64857M 0.66M
Total cashflows from investing activities -0.03646M -0.08915M -0.01047M -0.01674M -0.00702M
Net borrowings -0.05992M -0.03451M -0.05829M -0.08924M -0.08924M
Total cash from financing activities 0.12M 16.30M 36.69M 3.98M 12.72M
Change to operating activities -0.88952M -0.39329M -0.62403M 0.07M -0.31778M
Net income -13.80651M -12.84706M -15.30935M -10.05968M -12.33783M
Change in cash -19.03302M 6.69M 18.92M -5.20301M -0.83565M
Begin period cash flow 34.81M 28.12M 9.20M 14.40M 15.24M
End period cash flow 15.77M 34.81M 28.12M 9.20M 14.40M
Total cash from operating activities -20.03584M -12.33727M -17.33007M -9.43112M -13.95482M
Issuance of capital stock 0.31M 17.18M 39.24M 4.36M 13.08M
Depreciation 0.10M 0.05M 0.08M 0.11M 0.03M
Other cashflows from investing activities -0.02915M -0.02915M -0.02915M -0.02915M 0.00000M
Dividends paid 0.00000M 0.00000M 0.00000M 0.00000M -
Change to inventory 2.45M -2.21071M 0.19M 0.65M -0.66293M
Change to account receivables -3.94034M -0.44768M -4.21636M 4.77M -1.67709M
Sale purchase of stock 0.32M 17.18M 39.24M 4.36M 13.08M
Other cashflows from financing activities -0.13241M -0.83697M -2.49265M -0.29277M -0.36232M
Change to netincome 0.06M -1.30745M 2.31M -0.27499M -0.31474M
Capital expenditures 0.00731M 0.09M 0.01M 0.02M 0.00702M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -3.94034M -0.44768M -4.21636M 0.79M -1.33194M
Stock based compensation 0.97M 1.51M 1.88M -0.01202M 0.09M
Other non cash items -6.33158M 0.46M -2.09608M -0.01202M 0.09M
Free cash flow -20.04315M -12.42642M -17.34054M -9.44787M -13.96184M

Fundamentals

  • Previous Close 0.006
  • Market Cap31.43M
  • Volume1599709
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-12.83227M
  • Revenue TTM3.43M
  • Revenue Per Share TTM0.001
  • Gross Profit TTM 3.63M
  • Diluted EPS TTM-

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ATH
Alterity Therapeutics Ltd		 - -% 0.006 - - 9.16 1.38 164.75 -1.1132
CSL
CSL Ltd		 -0.13 0.05% 279.43 35.44 31.35 9.60 5.16 10.91 34.93
TLX
Telix Pharmaceuticals Ltd		 0.17 1.14% 15.14 748.00 21.01 8.47 28.69 8.21 177.65
NEU
Neuren Pharmaceuticals Ltd		 -0.33 1.63% 19.92 15.98 38.46 11.63 13.15 10.65 12.39
MSB
Mesoblast Ltd		 -0.055 4.68% 1.12 - 769.23 116.88 1.12 126.11 -19.3368

Reports Covered

Stock Research & News

View All

Profile

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Alterity Therapeutics Ltd

350 Collins Street, Melbourne, VIC, Australia, 3000

Key Executives

Name Title Year Born
Mr. Geoffrey Paul Kempler B.Sc, B.Sc. Co-Founder & Non-Exec. Chairman 1955
Dr. David A. Stamler M.D. Chief Exec. Officer 1961
Ms. Kathryn J. E. Andrews Chief Financial Officer 1967
Dr. Rudolph Emile Tanzi Ph.D. Chief Scientific Advisor and Member of R&D Advisory Board 1958
Dr. Steven D. Targum Chief Medical Advisor NA
Dr. Robert Cherny Head of Research NA
Mr. Phillip Allen Hains BBus(Acc), CA, MBA Company Sec. 1959
Mr. Geoffrey Paul Kempler B.Sc. Co-Founder & Non-Executive Chairman 1955
Dr. David A. Stamler M.D. Chief Executive Officer 1961
Ms. Kathryn J. E. Andrews B.Com, CPA Chief Financial Officer 1967

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).

Our Company

Useful Links

Contact Us

Market Research

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.